WELCOME
In hospital neonatal care, NeoDuoFlo® stands out — a dual-lumen orogastric feeding and decompression tube dedicated to safer, clinically informed support for neonatal patients.
Our device is aiming to transform neonatal care by reducing feeding complications, easing clinical workflows, and improving care outcomes for tiny fighters everywhere.
ABOUT US
Founded by professionals in neonatal care
NeoDuoFlo® was founded by Francesca (Franki) Coulthurst, a practising neonatal intensive care registered nurse who identified the critical need for a safer, more efficient neonatal feeding tube while working at the cot side in Queensland neonatal intensive care units.
NeoDuoFlo® is an Australian-based, female-owned organisation, motivated by a mission that’s close to our own hearts; improving outcomes for preterm and critically ill babies by developing innovative, clinically driven medical devices. With deep clinical insight and cutting-edge design, we’re proudly redefining neonatal care standards.
OUR PRODUCT AND TECHNOLOGY
Reducing the need for multiple interventions
Prioritises safety, comfort, and ease of use for healthcare providers, helping to prevent complications like feeding intolerance and aspiration.
Our dual-lumen design allows simultaneous feeding and gastric decompression, reducing the need for multiple interventions.
Crafted with biocompatible materials in a compact, easy-to-insert configuration, NeoDuoFlo® addresses the unique physiological needs of neonates.
HOW WE HELP
For clinicians
Designed for neonatal clinicians, including nurses and doctors caring for preterm babies on breathing support: one tube for feeding and decompressing, at the same time.
HOW WE HELP
For babies
Designed for the smallest patients on breathing support, with gentle care in mind.
Designed for neonatal intensive care units seeking to keep feeds going and reduce avoidable work-ups. Outcomes will be measured in clinical upcoming studies.
For hospitals
HOW WE HELP
DEVELOPMENT PROGRESS
Key milestones
AUGUST 2026
Manufacturing prototypes built by an ISO 13485-certified contract manufacturer, advancing the technology beyond proof of concept.
DECEMBER 2026
Planned neonatal preclinical study ahead of first-in-human studies.
JUNE 2026
Completed independent bench testing with the Medical Device Partnering Program at Flinders University.
SEPTEMBER 2026
PCT international patent application filed, building on two Australian provisional patents. Australian trade mark registered, with a Madrid Protocol application.
2027
First planned
in-human studies.
OUR FOUNDER/CEO
Francesca (Franki) Coulthurst
A practising neonatal intensive care registered nurse with years of experience working cot side in Queensland neonatal intensive care units.
TEAM AND
Expertise
NeoDuoFlo is supported by experienced advisers across regulatory, go-to-market, finance and intellectual property.
SUBSCRIBE FOR
News & updates
Keep up with our progress, including key milestones, study results, and neonatal news. Join us in setting a new gold standard for safer, innovative neonatal care.
AWARDS AND
Recognition
-
Stanford Biodesign Impact1 Innovators Forum and an invitation to the Impact1 Pediatric CEO Summit at Stanford in October 2026
-
Winner of the QUT BridgeTech Pitch Event
-
Winner of the ANFF-C and In-House Ventures pitch night
-
ANFF-C Gate 1 funding secured
-
Selected for the BEDA MedTech Accelerator at J.P. Morgan Healthcare Week in January 2027
-
AusBiotech Industry Growth Program.
